
Chinese biopharmaceutical company founded on 25 January 2002 and headquartered at 399 Libing Road in the China (Shanghai) Pilot Free Trade Zone, listed on the Shanghai STAR Market under code 688336 since 2020 and holding national high-tech enterprise status. Specialises in the research, manufacture and sale of antibody medicines, running a national engineering research centre for antibody drugs and a national enterprise technology centre together with monoclonal antibody production lines of more than forty thousand litres. Its lead products include the TNF fusion protein Yisaipu and the HER2 antibody Saipuding covering autoimmune disease and oncology, and it has more recently obtained approvals for the IL-17 antibody Yisaituo for moderate to severe plaque psoriasis and a subcutaneous antibody injection.
Laissez votre note